@article {35, editor = {,}, title = {Risk of serious adverse effects with Janus kinase inhibitors}, volume = {61}, number = {3}, pages = {35--35}, year = {2023}, doi = {10.1136/dtb.2022.000078}, publisher = {British Medical Journal Publishing Group}, abstract = {Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/61/3/35}, eprint = {https://dtb.bmj.com/content/61/3/35.full.pdf}, journal = {Drug and Therapeutics Bulletin} }